Loading...
Publication
Medicamentos antidiabéticos no indivíduo com obesidade e o impacto na função muscular
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 3.96 MB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Os agonistas do recetor peptídeo 1 semelhante ao glucagon (GLP-1 RA, do inglês glucagon-like peptide-1 receptor agonists) são fármacos utilizados no controlo da glicemia e na redução de peso corporal. No entanto, a perda de peso induzida por estes fármacos pode causar um estado catabólico que afeta a massa, a força e a função muscular. Isto pode levar ao desenvolvimento de sarcopenia, caracterizada pela perda progressiva de massa e força muscular. Esta condição, embora associada ao envelhecimento, também ocorre em jovens e em pessoas com excesso de peso ou obesidade.
Esta revisão teve como objetivo investigar a relação entre a terapia com GLP-1 RA e os efeitos sobre a massa, a força e a função muscular, considerando a perda de peso associada à administração estes fármacos. Após a formulação da questão de investigação, foi elaborado um protocolo de pesquisa que incluiu os termos de busca ("GLP1RA" OR "GLP 1 R A" OR "GLP 1 receptor agonist" OR "glucagon-like peptide-1 receptor agonist" OR "GLP1 analogs" OR "dulaglutide" OR "liraglutide" OR "semaglutide" AND "sarcopenia" OR "sarcopenic" OR "muscle strength" OR "muscle mass" OR "physical strength") nas bases de dados de referências PubMed, Web of Science, B-on, Scopus e Elsevier. Após a aplicação dos critérios de inclusão e exclusão, foram selecionados e analisados 24 artigos publicados entre 2016 e agosto de 2023, com 13 estudos realizados em humanos e 11 em modelos murinos.
Os GLP-1 RA apresentam efeitos variados sobre a massa, força e função muscular. Em indivíduos com diabetes mellitus tipo 2 e obesidade, fármacos como o dulaglutido e o exenatido estão associados à redução da massa de músculo esquelético. Em contraste, o liraglutido, lixisenatido e semaglutido demonstram efeitos benéficos na composição corporal. Em modelos murinos, alguns agonistas promoveram melhorias na força muscular. Além disso, alguns agonistas revelaram potencial para aprimorar a coordenação motora e a função exploratória, destacando a complexidade dos efeitos de GLP-1 RA e a necessidade de investigação adicional.
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are drugs used to control blood glucose levels and reduce body weight. However, the weight loss induced by these drugs may cause a catabolic state that affects muscle mass, strength, and function. This can lead to the development of sarcopenia, characterized by the progressive loss of muscle mass and strength. Although this condition is associated with aging, it also occurs in young individuals and those with overweight or obesity. This review aimed to investigate the relationship between GLP-1 RA therapy and its effects on muscle mass, strength, and function, considering the weight loss associated with the administration of these drugs. After formulating the research question, a search protocol was developed that included search terms ("GLP1RA" OR "GLP 1 R A" OR "GLP 1 receptor agonist" OR "glucagon-like peptide-1 receptor agonist" OR "GLP1 analogs" OR "dulaglutide" OR "liraglutide" OR "semaglutide" AND "sarcopenia" OR "sarcopenic" OR "muscle strength" OR "muscle mass" OR "physical strength") in the reference databases PubMed, Web of Science, B-on, Scopus, and Elsevier. After applying inclusion and exclusion criteria, 24 articles published between 2016 and August 2023 were selected and analyzed, with 13 studies conducted in humans and 11 in murine models. GLP-1 RA exhibit varied effects on muscle mass, strength, and function. In individuals with type 2 diabetes mellitus and obesity, drugs such as dulaglutide and exenatide are associated with a reduction in skeletal muscle mass. In contrast, liraglutide, lixisenatide, and semaglutide show beneficial effects on body composition. In murine models, some agonists promoted improvements in muscle strength. Additionally, some agonists revealed potential to enhance motor coordination and exploratory function, highlighting the complexity of GLP-1 RA effects and the need for further investigation.
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are drugs used to control blood glucose levels and reduce body weight. However, the weight loss induced by these drugs may cause a catabolic state that affects muscle mass, strength, and function. This can lead to the development of sarcopenia, characterized by the progressive loss of muscle mass and strength. Although this condition is associated with aging, it also occurs in young individuals and those with overweight or obesity. This review aimed to investigate the relationship between GLP-1 RA therapy and its effects on muscle mass, strength, and function, considering the weight loss associated with the administration of these drugs. After formulating the research question, a search protocol was developed that included search terms ("GLP1RA" OR "GLP 1 R A" OR "GLP 1 receptor agonist" OR "glucagon-like peptide-1 receptor agonist" OR "GLP1 analogs" OR "dulaglutide" OR "liraglutide" OR "semaglutide" AND "sarcopenia" OR "sarcopenic" OR "muscle strength" OR "muscle mass" OR "physical strength") in the reference databases PubMed, Web of Science, B-on, Scopus, and Elsevier. After applying inclusion and exclusion criteria, 24 articles published between 2016 and August 2023 were selected and analyzed, with 13 studies conducted in humans and 11 in murine models. GLP-1 RA exhibit varied effects on muscle mass, strength, and function. In individuals with type 2 diabetes mellitus and obesity, drugs such as dulaglutide and exenatide are associated with a reduction in skeletal muscle mass. In contrast, liraglutide, lixisenatide, and semaglutide show beneficial effects on body composition. In murine models, some agonists promoted improvements in muscle strength. Additionally, some agonists revealed potential to enhance motor coordination and exploratory function, highlighting the complexity of GLP-1 RA effects and the need for further investigation.
Description
Keywords
Agonistas glp-1 Sarcopenia Massa muscular Força muscular Diabetes mellitus tipo 2 Perda de peso